Apr 10 |
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
|
Mar 29 |
Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4
|
Mar 27 |
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
|
Mar 26 |
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
|
Mar 26 |
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
|
Mar 22 |
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
|
Mar 22 |
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
|
Mar 21 |
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
|
Mar 21 |
Argenx gains after setback to Roche/Chugai myasthenia gravis therapy
|
Mar 19 |
Reasons to Invest in argenx (ARGX)
|